RETA - Earnings call transcript Q2 2020 | Reata Pharmaceuticals Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and welcome to the Reata Pharmaceuticals Second Quarter Financial Results and Update Development Programs Call. My name is Sheryl and I will be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded.

Before we begin, I'd like to go over a few housekeeping rules. An audio recording of today's webcast will be available shortly after the call today at Reata's Web site at reatapharma.com in the Investor Section.

with the please company's proceeds statement the company of disclosure press the its note remarks, forward-looking Before release. The on company today's statements call. will make forward-looking differ noted There expectations, filings. many factors could results are that including the in to those company's SEC cause from guarantees are future the not outcomes. Today's of statements as no any Please also longer rereading. at time of only be replay comments August or XX, today's call made accurate note today, on XXXX, webcast transcript that speak any of and may the

open that the welcome that questions will up accommodate the for yourself of ask we Following Please Mr. prepared many We call you President Vice to Strategy. questions. remarks, now as Jindal, possible. as one we limit Vineet please question so can

You may begin.

Vineet Jindal

release to XXXX financial quarter with these programs. press you. the second on press a Chief to for be and found This discuss a I'm Huff; of Colin our Research Officer, of today Manmeet and Good and morning, Management's Thank by and and Financial Soni; section at morning our site Development of results release Officer, our the reatapharma.com. Warren summary Chief a welcome provide review can Meyer. of to Executive Operating issued our Web Chief development and Officer joined the we call results Reata our Chief Officer, Investors

Warren, limiting Before turn I now we're per remind to questions turn you. the I'll that the to call callers one Q&A. over please, to to Warren, I'd it our like caller, over during

Warren Huff

lead I'll the X. FDA, syndrome regulatory the status respect on ongoing thank I'll to approval potential Manmeet company's a products patients an the a for of the with treatment an begin and Colin our on of call. call, quarterly everyone. update programs for of with provide Slide and regulatory interactions the of Thanks, with on Alport clinical summarize review with will omaveloxolone. Vineet. a status bardoxolone On the on Good you financials. our for bardoxolone And us joining will morning, update today's path

the assumption Phase the the submitting of the concern the We engaged with So consider delay following be believe basing the where on based year announcement the November in address study was much not had for the with of year would data. by NDA year that meeting recommended XXXX, expressed and results. year an been and data. data. to NDA one safety for CARDINAL NDA invited of III C recommendation in Type provided we FDA The FDA a their discuss FDA questions us the that with for additional waiting two accelerated that the in one data two part from suggestions one to efficacy data and We've analyses year one we've alone their there on submission approval is year their

a pre-NDA content delayed meeting. NDA the the we and Following FDA IND meetings including at by informal raised and of and the written We the granted analyses questions C meeting FDAs requested the questions. meeting, Type we've requested addressed requesting to address review a interactions, the submission, recently while had to were We the plans. pre-NDA series discuss to submissions FDA meeting and a

during pre-NDA meeting questions the data the of in handled One the be to resolved two review should NDA key the be year is how process.

NDA. before from the year continues accelerated makes process III results the an the submit year also could review the portion but of CARDINAL Alport date, rather PDUFA about CARDINAL. the and year file that second second extent If for wait and accelerated the this NDA to recommend during to year the available an first to second to data this guidance be consideration acceptable data during The result are the of would timeframe, may a current to Phase data compared of the for based able approval be our in we This could permit than fourth for the year bardoxolone year. the for quarter us FDA we Our until FDA plan by during quarter the determination approval would full the on may submit one filing to of filing from approval. XXXX syndrome This has but the full end of file approval, of been approval. delay accelerated

are Colin of that undertaken provide more basis. and ensure timely necessary the on assumes activities we data lock CARDINAL on data to maintain providing that database data. year a details to the Of complete year the FDA the course, two the year data will can to positive be this integrity we've timing timely the two two steps and

the proceed for Moving the the to for the I'll this study of regulatory the submission from in from on Ataxia X, submission. provide NDA X October the After marketing update announcement proposals to States. Slide XXXX. regulatory year a an with Part with planned the Omav pathway the to to path MOXIe omaveloxolone. data United engaged X Part to with subject to is treatment approval MOXIe our been discussion authorities of discuss use data the We've Friedreich's for in of FDA study We

patients Part preliminary XX that magnitude with FDA it pandemic If The the need would conduct the alternative small number and review who FDA any the a standards. acknowledged the a study meet clinical that the been provide rate of a explained on constraints evidence study FDA now FA The a FDA launching controlled life availability crossover the could and the to trial company that to mFARS we would stated the submit commitment the could and unmet acknowledged The conduct can pandemic of a data pivotal emphasized whether lends could impact Research and study. in In difficult pivotal are description endpoint a trial FA study study its MOXIe open quarter the the will study consider fourth be Omav in study of clinical to design randomized that the FA in number confirmatory support study, placebo label the facilitate the The additional within Type and in conduct X preliminary study. based can the have a source effect to FDA have by opinion evidence effective to disease as the FA treatment research, extension persuasiveness key completed patients a the to the serve a Omav results. trial were for previously The the this the of would a that the adequate crossover options. to clinical the of trials. of of mFARS results FARA Ataxia an not on a pivotal study propose the meeting, confirms data all to with study reiterated as provided of limited measure Alliance as the prospective it with determine similar regulatory the positive being difficult meeting, the FDA the Community. progression very to be potentially on be clinical with the and additional evidence. exam comments the in trial not MOXIe investigators because study we'll information. asked of of X to effectiveness. neuroscience in like crossover concerns to or we study primary is We FA pointed that conduct patients recently threatening regulatory completed in the with the that additional that It's views mFARS FA ability an in of and Nevertheless, key second placebo convinced COVID- as COVID-XX and year additional that slow the of proposal, effectiveness. progressive proposals X MOXIe patients. results supported the clinicians guidance of reliability available patients its does to treated In of standards proposed for they're willingness single FARA, Omav that need agreed in FDA have without mFARS additional and of study of of sufficiently and an crossover Part second Part the early Part the MOXIe proposed would FARAH a new additional results second to approval that no which available C therapy the the us Our important evidence result we development clinicians leaders of response conducting FA MOXIe who the clinical options Friedreich's study long key accepts provide assuming effect. X from the to with delay We comments the crossover the proposal out because the of the

of and of the it Type pivotal an of only Regardless comment to United will C Our of we yet. a States. with the marketing data now plan FDA, benefit the without FA received I Colin crossover are FDA rejects of of the feasible to to just details update the on pursue the in first as If plan meeting company's provide by to like on quarter and an or the to of I'll minutes development second patients design XXXX. during NDA from call approval the programs. study we we proposal, the to the conduct be providing completed if the study ongoing having FDA. we're supportive, the would it's turn the the to proposed FDA add, meeting submit evaluate the suggested over not interaction the whether outside recently

Colin Meyer

Warren. Thanks

Approximately on their trial. MOXIe extension XX. of study Part XX-week will week As during they patients were group the treatment visit patients randomized completed as placebo, study. randomized would placebo in the patients to and MOXIe Part We in stopped four the compare X own the Patients at Warren it entered used After would in open change Part label MOXIe phase a the duration mFARS safety who measure X, change in treatment in and their to to MOXIe be mentioned had mFARS weeks crossover controls. the Part the X for XX the analysis. their extension use X

investigators can placebo. in therefore XX if the patients to during extension will MOXIe phase. be and as the of and analysis the and the in FDA were they to analysis analysis. MOXIe week the X their We Patients have it know not Part to treatment conducting efficacy or with of the mFARS do extension baseline like phase the blinded Omav assessments during same the for before extension from be like Part used Operationally value as been continued the they remained agreement who assignments have the would manner conducted most trial, receiving X. the have mFARS be rigorous informative would For

We be guidance the seeking with and analysis are finalized the of FDA. on will the discussions during our details specific many methodology

we're as Moving and X CKD our process programs two Warren III of year Phase Slide mentioned completing to portion our study. the on earlier, the of CARDINAL in

pandemic ongoing serious as emerged our XXXX, guidance a clinical of quarter accordance and patients the and in studies maintaining a and while safety measures COVID-XX of of conduct EMA. by As first we provided the health the public protect involved workers series our FDA the healthcare with with in the undertook health to studies, implications of during

home have patient visits and to blood we at an implemented draws safety. of assess visits example, in-clinic to to the For collect as necessary use when alternative

consistent III We to anticipated patients approximately the occur last the XXX visit. year almost timeline. of taken COVID-XX. At the final year remote fourth have that timeline be to as visits on sites At on-treatment result believe the cohort data The to time pandemic current is or metrics. of time, by availability two for of the site all allowing randomized during this for which response a our in affected of study XXXX, measures is completed this and patients. to delivery the also are home Phase are XX% Currently, quarter on arrange cardinal two unlikely study drug the we with to operational pre-COVID-XX monitoring based

is with in began eGFR June the enrollment emergence to conducting to ADPKD able treatment In that study range approximately the hold patients lift one of are age Similar half are FALCON international screening sites CARDINAL, function able bardoxolone year of FALCON In years XX. patients. after described randomize screen an We support are Slide off-treatment to we III March patients on and and temporarily enrolling wide screening study XXXX and of approval. XXXX, addition to paused two due of we Falcon and COVID-XX. the new all of and with kidney a CARDINAL study, as two to and in the currently, patients P to assessments

The to COVID-XX reached due of year meaningful trial. first we few patients response we data FALCON now effective COVID-XX. no second implemented the in impact and on the conduct to anticipate the to The have have measures integrity of been

also Medicine, call, year last quarter patients journals of form genetic I Invitae of like the patients these tested highly nephrologists XX% syndrome of testing in Alport initiative. were XX% More cause genetic background Alport published Today, program mutations described findings the group positive positive syndrome that more the XXXX clinical syndrome genetic this that gene was with some misdiagnosed. recently, XX% code, approximately are have forms in the for underlying CKD with are sponsored various of of Recent England for suggesting Alport in Reata by have same and collagen consistent proportion help New first Several to genotyped with CKD, cause CKD. earnings our patients as be and a one kidney a therefore estimated During IgA for to patients genes of Alport for found of other who with currently identify of nephropathy Journal research ADPKD. with the over positive provide respective to than I'd syndrome, the concluded kidney the basis these of to had published disease. briefly XX% that nephropathy and and often In IgA genetic patients may in study a prevalent in nearly diagnosis tested that and which assessed patients [indiscernible] cause genes XX% identical mutations familial that of the syndrome. collagen studies test mutations FSGS have

to Slide Moving on XX.

XX% investigator and effects inflammation, which up of As organs. in other announced, trial shown randomized sponsored result has patients a BARCONA chronic endpoint complications trial that hospitalization caused eGFR we and treatment is be lungs, suffering Acute kidney study mitigate of for NYU researchers placebo to occur dysfunction trials XX lung clinical less than enrollment include of and survival previously patients to disease. systemic kidneys animal have types COVID-XX. with safety. kidney double Serious enroll at criteria reported various assess patients systemic Phase blind all in of that prior survive days, to of from have with safety forms XX mL/min. three kidney and its been patients, up up replication do kidney the COVID-XX initiating a bardoxolone have XXXX further are of COVID-XX patients days injury, paused study excessive are for duration viruses, primary activity in and models X suppress of improvements hospitalized more function who and mechanical multiple not failure, patients of several anti-inflammatory then XX% any Bardoxolone safety COVID-XX. to enrolled The patients. an and of and who five of of can in will heart over the controlled, To injury inflammation, risk, acute and analogues intubated enrollment of Major and of XX exclusion hospitalized will by to in increased ventilation demonstrated after patients models on or invasive initial are or to

executive committee by monitoring requested the supplies design all as a steering results. an Phase the in the update NYU, safety the Phase week. activity, over enrollment meets As the X in trial a a gated further of providing trial is feasibility representative be on any other trial potential every on involved trials conducted on now well was safety be trial. of financial X the to drug board and overseen by provide and study's Phase Manmeet at as will based I'll of call NYU with conducting the X will company's assessment turn Reata that data to an as

Manmeet Soni

for quarter us for Please of to of everyone. morning, Thanks, Thanks joining summary today. Colin, release financial for XXXX. our refer earlier our press and results a today second issued good the

through want from financial the Slide second developments walk summary, quarter, on highlight I that Before key which are few to a I XX.

$XXX a from common strategic of completed strengthened future Blackstone $XX investment issued. royalty we million balance that First, comprised payments sheet million and for for stock Reata's $XXX million

to value of accounted we In in on payments like to million. a $XX $XXX.X the continued transaction would We Regarding note in recorded we payments the as for future loans, payoff involvement. fair components, the extinguishment I shares. by liability paying loss next the relative the the for to significant $XX.X term million Blackstone to of and the term allocated interest connection resulting million million based the consideration that total with due we over accounting loans. off to of years the a investment, investment two three common $XX.X term our our related liability approximately on of cash would of debt our loans, royalty save

X XX, and last June with related during balance our agreement financial to approximately continue we of to in ended Moving with decreases through fund XXXX. results in XXXX. expect quarter activator recorded and The operations and rights the which the three quarter revenue months in primarily programs, which were cash $XXX.X license Slide our our XXXX, XXXX reacquire the on to XX, in NRF we to to XXXX in of cash write-off second available revenues to due million cash AbbVie equivalents occurred ended deferred the no of resulted remaining for

$XX.X $XX.X our for to million of expenses, compared second the quarter quarter XXXX. to R&D the Moving expenses were million for

in expenses $XX.X $XX.X R&D million compared million were at year-to-date to XXXX. Our

compared $XX.X for million quarter for $XX.X expenses quarter million, to of were G&A the XXXX. the second Our

Our expenses $XX.X year-to-date, XXXX. in $XX.X were million compared to G&A million

the second Our XXXX. of were million operating expenses the $XX.X $XX.X quarter for compared to for quarter million,

loss on was per diluted Our both for basis. or the net quarter share $X.XX a basic $XX.X million and

to or diluted basic and of share basis $X.XX compared a loss million $XX.X quarter a the per As XXXX. on both net second for of

and these to future compensation expense measures of liability extinguishment stock of on measures non-GAAP on based Slide to interest loss debt from royalties. related exclude sale Moving expenses, XX, non-GAAP non-cash

non-GAAP $XX.X the quarter of for XXXX. million for $XX.X second compared Our the were to expenses quarter R&D as million

$XX.X were to expenses R&D million XXXX. million compared non-GAAP year-to-date, Our $XX.X for

Our million the to of for second quarter quarter the non-GAAP million for expenses XXXX. G&A as compared $X.X $X.X were

compared expense for Our year-to-date non-GAAP were $XX.X million, million $XX.X to XXXX.

for R&D non-GAAP expenses to stage increased the support due advancement clinical pipeline development to and G&A Our headcount the programs. increased quarter late primarily in to our

expenses we non-GAAP primarily increased headcount activities. increased expanded expenses support as clinical higher increased to R&D costs, due personnel year-to-date Our development our cost and manufacturing to studies and our

readiness experienced G&A personnel non-GAAP That our activities. also as increases remarks. Our increases commercial activities in to support well expenses concludes our in in development prepared as growth

We questions. will line now open for the

Operator

Thank you.

from begin question-and-answer first from now [Operator Our Citigroup. Nochomovitz will session. Instructions] the We question Yigal comes

Your now line open. is

Yigal Nochomovitz

two FDA as COVID. potentially comments Bardoxolone, standards additional requested on the may the given what the options expand verbal consider on you. to analysis Omav, also the was new some that those in the you or trial analyses Warren, on And were? be part possible Alport then, to Were think emphasizing were based by on subsequent as or regulatory first additional that the were those Type that willingness those study, could meet question, I feedback, well regarding there mentioned comments if the Just FDA meeting Thank written C to comments? writing you've available all in not that a acknowledging a regarding

Warren Huff

occurred half meeting. crossover their sent the question. the meeting. preliminary the comments and all the happened all about discussion the were to the take consider of the willingness after to during I'll comments It study about the Yes. first Yes, options

Yigal Nochomovitz

Okay, thank you.

Coin Meyer

And answer your I will second question.

data review analyses about your new well pre-specified also questions suggested. demonstrating did provided action we pharmacodynamic as not mechanism So clinical The as they the the about provide primarily efficacy. FDA was well and of have team we In pre-clinical the to a data, program as response to sensitivity questions They as analyses, safety. profile. questions,

informal and their So we and amendments IND meetings we addressed well as a address formal believe that comprehensively as comments. questions these

to As addressed comments. to I request waited we we believe we recently And we FDAs stated, a and the to had granted were as meeting. have that know, submit you questions pre-NDA pre-NDA meeting

Operator

you. Thank

question Maurice comes next Jefferies. Our from from Raycroft

Your line is now open.

Maurice Raycroft

and the clarity path the providing regulatory for thanks today. And

out say X not FDA study and For is about they Part the supportive to crossover efficient. single if view study as the approval. results just you can more convinced of if when And FA wondering, are find why public, disclose MOXIe you'll

Warren Huff

Maurice. Sure,

largest the controlled of was mFARS study believe approval. are supportive we MOXIe data placebo conducted the to-date. So

a it with a .XXX. know, pre-specified of the have could wanted involved you value p approximately XXX We As value. p endpoint patients. The FDA hit primary lower

duration value in have effect unsure the of Our lead treatment We for National Study. been if observed and treatment than much investigators believe could the History the maximal was variability the lower this p therefore was lower. much

Additional primary imbalances sensitivity analysis for characteristics that effects. conservative treatment estimate and a be suggested may the of analyses controlling the baseline

pre-specified included in conducting were hierarchy. the to the them support descriptive the the primary real to almost FARA worsened, the analysis of improved data of time merit all of we've point on but Importantly that only agreed provide all Omav every MOXIe with analysis. and major as all the as investigators prior mFARS trial, We who favored while to risk endpoints sections conclusions the FDA pre-specified review. patients reviewed baseline they placebos powered, effect subgroups data link. the factors that the global four of from of all age including the data of most Omav, experts, criticism and regulatory clinical should improved and placebo The rapid data for the well is JX versus the represent secondary onset populations the at We pediatric not with treatment favored secondary endpoints repeat the those missed and progression, that patients including knew

had randomized value [all] important p most PGIC frequency significant patients. reported secondary Omav first [ph] nominally activities of is questions the or The the significance The favored and CGIC living and a of my time. value Omav, with of investigators .XX, approach and of ADL daily result. in favored to was over p separate the population ADL all and all significant .X patient across analysis a primary us different

right crossover those it trial. approval. data, the reasons, We're for should to now and the So with we support FDA the think discuss engaged

we conduct believe to actually that we we As we in that course, could design fourth execute design, we analysis the agreement review the sure pending in make analysis. of stated, the that want FDA quarter, with before of they're

Operator

Thank you.

from Schwartz Our from next question comes Joseph SVB Leerink.

Your line is now open.

Joseph Schwartz

Probably what you just are Omav, like year of and to FDA one merits data scenario scenario or [indiscernible] what the scenarios. through views two the of the see aspects FDA CARDINAL on questions the could goes that year FDA the walk would the data, us the for the

Warren Huff

were FDA the about CARDINAL had cutting Joe, your that your data? questions the question out was first about one You

Joseph Schwartz

Yes.

Specifically what aspects, them you laid it helpful out like was how for Omav.

year one do they're would So that the more by year convinced what we what not data data aspects understand, Bard? can lead same specifically? them of could feel you And way two differently positively? the So thing for then, to

Colin Meyer

Yes.

mechanics as So to formally pre-NDA of actual the IND mentioned, amendment. provided in a analyses, sensitive And post now, meeting, submitted discuss that we they hoc would recommended, address well which pre-specified specific as submission. was scheduled all And we're I analyses as we the where their questions. have which

the year. year influence this And could our data. with FDA is upon based the that handle the quarter And so the of to We'll timing. two how Warren in one as discuss to year mentioned, file fourth data plan

Joseph Schwartz

it Right. aspects was But was the the data else? something it what it of year GFR, proteinuria, was or one

Colin Meyer

that can as understand they the effects They pharmacodynamic that the were asks just questions FDA the well analysis as typically the better about trial, so results. standard of

Joseph Schwartz

at see, did to two that? give And then, data FDA the with into what insight like they any you years

Colin Meyer

and two same support so approval. full FDA the years of meeting, to It's they full data since stated wanted pre-IND our that

Warren Huff

the for commented see they the that didn't two they and much in year commented They waiting context data. delay

Operator

Thank you.

comes Our next question Stifel. Samimy from Annabel from

open. line Your is now

Annabel Samimy

wait is sounds for like some FDA going year Just, that two data, year I that that what regardless, from seems guess, because questions to one the like data. on they it it have

if delay see might tell separately C us the to please wasn't might be the tiered Thank impact And the sufficient when XX the before And then, additional data meeting? on see crossover Blackstone satisfy study, will does clear is the guess Type the from you their job the you I that? conducted that can you. whether Omav, So how first so, know we to exactly FDA whether there? I accepts patients needs royalties

Warren Huff

I'll take diligence of conducted after the Type that. part Blackstone reference was the meeting Bardoxolone. first for C The

Manmeet Soni

is mid digit royalties are There or low same, the remain this. of high because of Blackstone It single but start the either doesn't that's impact no royalty it. they mid those, from single they in digit, at change single on tier and can down to digit,

Colin Meyer

not to year until on of the one first just data the wait so to And to file the two address the part of question, year data. your our current is plan basis

meeting guidance. However, additional FDA pre-NDA provide in the may

is current accelerated file And so our why year on that's data for approval. to plan one the

Warren Huff

our the We believe plan before IND meetings. end. the initial was the we that questions submissions were in requests, made and meeting pre-NDA that file their made raised your address to clear When we we amendments

Annabel Samimy

-- on then, And the clarity Omav on the just Omav? the

Warren Huff

the was question? What

Annabel Samimy

to me might we wasn't It when is crossover hear to the whether accept design. clear FDA going study a

Colin Meyer

There data make of see that'll sure. make course, do to a actual and decision, plan they before informative period to will ultimately out for aware I'm informal then they'll And time the they meetings want be them, which final themselves analysis most working some the a take of of process here. offered with that,

Operator

you. Thank

next Our comes from Skorney Brian from question Baird.

Your line is now open.

Brian Skorney

Hey, good question. morning, Thanks my guys. taking for

study magnitude that they want want to where X with statistical normally NX wiggle sufficient consider across just primary can here they it's matter or here? talk it Would I that room primary in support lower mean, it how update, that's is Or to an evidence? mean, analyses wanted that like a Part you MOXIe the is a Omav in And unclear, of terms of about significance? what issue coming the Is p they division a value lot -- approval? the of On is divisions. did not there's for considered regulatory I secondary the their of agency a endpoint? And seems down it be around on data needing the a deemed sufficient? endpoint confirmatory single

Colin Meyer

follow think, approvals. for And so single study trying just to regulations they're have the they I

they wanted so that And us told additional information. they

they there's so ways few that, different to to provide a discussions, receptive then the crossover most And design. seem

we're additional additional information them to to provide So proceeding that's how provide with persuasiveness.

Brian Skorney

data trial understand of terms the timing last year much of November And one be XX? two you date on year one design, from for to year in data the in help announced the pretty can available the after why me year expect just was terms then, wouldn't CARDINAL, you

Colin Meyer

That Yes. is expectation. the

is COVID-XX two So have its available we year our that in be to the guidance reasons fourth We unlikely year. mentioned. data now think of for by this affected the I quarter will the

in obviously, there that order be the NDA, provide to to so has analysis. And to

the the two year year FDA We formally the delay stated, requires plan datasets that one it. data have if the the to quarter. and submit data, said, file is update first would and being the by submission our until the on filing to year That end as we initial

in time. to potentially And not a provide so mechanisms too potential difference data. There's the there's large other

meeting. And the so the that with pre-NDA discussing agency at we'll be

Operator

Thank you. comes Ha [Operator Instructions] BTIG. Our from from question Gon next Dae

Your line is now open.

Dae Gon Ha

and to timeline this mean, a submission guess of and second I the assuming couple go for of expectation I only there's data out. positive timeline wondering, be XQ that's you've XQ, just just approval this might for the data laid point, comes the 'XX the And seems naïve, year at extremely first So full and outlined wouldn't in sort quarter NDA for Alport, just the the of given you months. but wondering, be the the since of you've why planned out, just

If kind should for think guess, guess about year you. second data the into trial, if your same mean, put FDA And part do, what second FALCON three there I any we Alport design, you you approval? the out Thank of as year I the second period to the FALCON read given supplement we of the delay data, similar also kind ADPKD to month of with would and anyway. saying that through is in requiring regards trial I review is, the timeline look how

Warren Huff

Yes.

options or I got be have a example, supplement data for way about data think data and I is that the to And are timing, integrity are able this mean, there in fourth options if just year the The like a to we on worse. it the pandemic of impacted seek be or coming the to multiple the conceivably, it data that. coming months with timely was clear Today, still to the the could concern visits, but much quarter would thinking the us just have find impacted. NDA. to few accelerated close agree submit ago, about I to file with with don't two And add a -- to, some for we that. could the we that basis, been that didn't database not we the evolved -- see that. pandemic.

FDA with on discussion may let we basis proceed we're based the So be about we're they the data. open might we with pre-NDA how that way on we and And operating the on it able complexity, stuck one the an play today, that in tell time. be the timing, would with just year things the some believe submitted have probably, course, that they But wait the meeting, would two simply But have in. data. environment of if data if out us submit year in the currently about data submission to should of

Dae Gon Ha

The trial? about FALCON the question

Warren Huff

Yes.

does a of design approval. the similar one design A you year duration with was period treatment I was all or FDA. given REPRISE know, treatment by given think it I the read us through this to as supported a think for different not ADPKD, it which its to the trial, necessarily tolvaptan, company

this first is through year And duration. data, where but the FDA trial years one so time the data, two going is the there's in is

that again, which pre-NDA mentioned, we they've and And I we provided so some conduct they meeting. of recommended the as that around granted the questions was, analyses,

it. I'm And would sure mean you there's to not what potential so, be ADPKD. read read it's determined by any if through exactly through the

Operator

I'd closing to comments. Jindal presenters, have the to queue. At Vineet time, like back Mr. And this further for call no turn in we questions

Vineet Jindal

call for joining the on Thank us be the today. Thank much. so of you end Thank That today's call. you. you would

Operator

ladies gentlemen. for participation. conference you, and Thank you Thank This call. concludes your today's

disconnect. now may You

Reata Pharmaceuticals (RETA) 10 Aug 202020 Q2 Earnings call transcript